This shareable PDF can be hosted on any platform or network and is fully compliant with publisher copyright.
This publication has not yet been explained in plain language by the author(s). However, you can still read the publication.
If you are one of the authors, claim this publication so you can create a plain language summary to help more people find, understand and use it.
This page is a summary of: Abstract 2224: Re-engineering of the duocarmycin structural architecture enables tumour-selective CYP2W1-mediated drug activation in human colon cancer xenografts., Cancer Research, April 2013, American Association for Cancer Research (AACR),
DOI: 10.1158/1538-7445.am2013-2224.
You can read the full text:
The following have contributed to this page
